Here, we have constructed CAR T cells based on mesothelin polypeptide sequences that bind MUC16 to effectively eliminate MUC16-expressing ovarian cancer tumor cells and stem cells in vitro, as well as to eliminative ovarian tumor xenografts in vivo. Here, MSLN is linked to ovarian neoplasm.